





Vergleichende Bewertung der verschiedene Überwachungsstrategien zum Beweis der Abwesendheit Bovine Herpesvirus 1 in Milchviehbetriebe

Eine Fallstudie in RISKSUR project

**Stendaler Symposium 2017** 

#### A. Veldhuis<sup>1</sup>, I. Santman<sup>1</sup>, B. Schauer<sup>2</sup>, F. Waldeck<sup>1</sup>, <u>J. Mars<sup>1</sup></u>, C. Staubach<sup>2</sup>, G. van Schaik<sup>1,3</sup> <sup>1</sup>GD Animal Health, <sup>2</sup>Friedrich Loeffler Institut, <sup>3</sup>Utrecht Universität

\*\*\*\*







Comparative assessment of surveillance programs to prove freedom of bovine herpesvirus 1 in dairy herds in a disease-free and endemic situation

A case study within the RISKSUR project

#### A. Veldhuis<sup>1</sup>, I. Santman<sup>1</sup>, B. Schauer<sup>2</sup>, <u>F. Waldeck<sup>1</sup></u>, J. Mars<sup>1</sup>, C. Staubach<sup>2</sup>, G. van Schaik<sup>1,3</sup> <sup>1</sup>GD Animal Health, <sup>2</sup>Friedrich Loeffler Institute, <sup>3</sup>Utrecht University





### Introduction

- Surveillance design framework (SDF) was developed in RISKSUR, an EU project.
  - For the design, documentation and redesign of surveillance systems
  - available at <u>https://surveillance-design-framework.wikispaces.com</u>
- Apply SDF on surveillance systems to demonstrate freedom of disease
- Case study: Bovine herpesvirus 1 (BoHV1) causes Infectious Bovine Rhinotracheitis (IBR)
- EU Member States can obtain official BoHV1-free status
- there are differences in Europe in the approach of eradication.







Compare epidemiological performance of EU & alternative surveillance approaches using scenario-tree models and cost-effectiveness analysis





Design	Component	Action
CONVENTIONAL		
(EU)		
ALTERNATIVE		



Design	Component	Action	
CONVENTIONAL (EU)	Intake	Blood >9 months twice	
ALTERNATIVE			



Design	Component	Action	
CONVENTIONAL (EU)	Intake	Blood >9 months twice	
ALTERNATIVE	Intake	Blood >12 months once + bulk milk testing	



Design	Component	Action	
CONVENTIONAL (EU)	Intake Monitoring	Blood >9 months twice Yearly blood >24 months	
ALTERNATIVE	Intake	Blood >12 months once + bulk milk testing	



Design	Component	Action
CONVENTIONAL	Intake	Blood >9 months twice
(EU)	Monitoring	Yearly blood >24 months
ALTERNATIVE	Intake	Blood >12 months once + bulk milk testing
	Monitoring	Monthly bulk milk testing (≥9/year)

ž



Design	Component	Action
CONVENTIONAL	Intake	Blood >9 months twice
(EU)	Monitoring	Yearly blood >24 months
	Purchase	No action
ALTERNATIVE	Intake	Blood >12 months once + bulk milk testing
	Monitoring	Monthly bulk milk testing (≥9/year)



Design	Component	Action
CONVENTIONAL	Intake	Blood >9 months twice
(EU)	Monitoring	Yearly blood >24 months
	Purchase	NA
ALTERNATIVE	Intake	Blood >12 months once + bulk milk testing
	Monitoring	Monthly bulk milk testing (≥9/year)
	Purchase	Blood + bulk milk testing

ž





Design	Component	Action
CONVENTIONAL	Intake	Blood >9 months twice
(EU)	Monitoring	Yearly blood >24 months
	Purchase	NA
ALTERNATIVE	Intake	Blood >12 months once + bulk milk testing
	Monitoring	Monthly bulk milk testing (≥9/year)
	Purchase	Blood + bulk milk testing
	clinical signs	Nasal swabs PCR





#### Scenario tree analysis (Martin et al., 2007)

Purpose:

- 1. Calculate <u>sensitivity</u> of each surveillance design to *detect* an infected herd (intake)
- 2. Calculate <u>probability of freedom</u> from infection in a herd during 1 year of *monitoring* a herd's free status in both designs

ž



#### Scenario tree analysis (Martin et al., 2007)

Purpose:

1. Calculate <u>sensitivity</u> of each surveillance design (and components thereof) to *detect* an infected herd


2. Calculate <u>probability of freedom</u> from infection during 1 year of <u>monitoring</u> a herd's free status in both designs



#### **Monitoring freedom in different situations**

BoHV1-free cattle holding:

- CONVA.without purchase of animals from non-free holdings, assuming BoHV1 isALTendemic at country level
- CONVB.without purchase of animals from non-free holdings, in a situation in which the<br/>country is free from BoHV1
- ALT C. that <u>purchases</u> animals that originate from non-free holdings, assuming BoHV1 is <u>endemic</u> at country level




<sup>#</sup>provided that the animal level prevalence in the group of lactating cows is 10% or more



#### Monitoring of free status in *conventional* design


Yearly serology on all lactating animals





#### Monitoring of free status in alternative design

Monthly bulk milk testing





# Probability of freedom and cost-effectiveness of surveillance systems

A: endemic countryB: disease-free countryC: endemic + purchase



#### Probability of freedom and cost-effectiveness (monitoring)

Description	Mean probability of freedom per year (min-max)	Cost per holding per year (P5-P95) (€)
Conventional design		
Situation A	99.74 - 99.81	<b>979</b> (352-1,863)
Situation B	99.94 - 99.95	<b>979</b> (352-1,863)
Alternative design		
Situation A	99.95	<b>476</b> (432-513)
Situation B	99.99	<b>476</b> (432-513)
Situation C	99.89 - 99.95	<b>804</b> (714-962)

A: endemic

B: disease-free

C: endemic + purchase

## **Conclusion & Discussion**

- Monitoring free status:
  - Designs performed equally well in *disease-free* situation
    - Alternative approach most cost-effective



- In endemic situation, the mean probability of freedom was lower in conventional design
  - Low frequency of testing might hamper timeliness of detection
- Bulk milk test is 98% sensitive at within-herd prevalence of 10%
  - Performance of alternative design might be less effective compared to the conventional design at within-herd prevalence <10%</li>



### Take home message

- Assessment of various surveillance designs is useful towards optimizing animal health surveillance (eg. costs and sensitivity)
- for IBR: frequent bulk milk testing, in combination with clinical surveillance is a good and cost-effective alternative to yearly serology.









# Thank you for your attention!

# **Questions?**



a.veldhuis@gdanimalhealth.com

RISKSUR project ► www.fp7-risksur.eu



The research leading to these results has received funding from the European Community's Seventh Framework Programme (FP7/2007-2013) under grant agreement  $N^{\circ}$  310806.